The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
5091
October 23, 2024
View Complete Issue         Table of Contents 2019 
Clonidine Oral Suspension (Onyda XR) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clonidine Oral Suspension (Onyda XR) for ADHD
October 23, 2024 (Issue: 5091)
The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for treatment of attention-deficit/hyperactivity...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Clonidine Oral Suspension (Onyda XR) for ADHD
Article code: 5091a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.